Summary of COVID-19 amantadine studies
1. Rejdak et al., Amantadine in unvaccinated patients with early, mild to moderate COVID‐19: A randomized, placebo‐controlled, double‐blind trial
99 patient amantadine late treatment RCT: 39% improved recovery (p=0.03) and 89% lower progression (p=0.12).RCT 99 patients showing higher complete recovery rates with amantadine, but no significant difference in progression. Authors suggest amantadine's central nervous system effects may have contributed to faster recovery by reducing neuropsychiatric symptoms.
Sep 2023, European J. Neurology, https://onlinelibrary.wiley.com/doi/10.1111/ene.16045, https://c19p.org/rejdak
2. Barczyk et al., Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study
186 patient amantadine late treatment RCT: 13% higher mortality (p=0.83) and 18% lower ICU admission (p=0.75).RCT 186 hospitalized COVID-19 patients showing no significant differences with oral amantadine compared to placebo.
Jun 2023, Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S0954611123000860, https://c19p.org/barczyk
3. Weis et al., Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial
242 patient amantadine late treatment RCT: 48% worse recovery (p=0.1).RCT 242 non-hospitalized COVID-19 patients showing no benefit of amantadine for disease progression.
Oct 2023, Clinical Microbiology and Infection, https://www.sciencedirect.com/science/article/pii/S1198743X23003014, https://c19p.org/weis